News Amgen Inc.

Equities

AMGN

US0311621009

Real-time Estimate Cboe BZX Other stock markets 12:12:00 2024-04-19 pm EDT			5-day change	1st Jan Change
266.7 ^USD	+1.49%		-0.19%	-7.38%

Apr. 17	UBS Adjusts Amgen's Price Target to $284 From $314, Maintains Neutral Rating	MT
Apr. 16	Amgen Plans for Phase 3 Trial of Tezepelumab for Lung Disease	MT

Summary

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

Amgen : First Cancer Diagnosis Led to a Dark Place—Aiding Another Helped Lift Him Out of It	Apr. 17	PU
AMGEN TO PRESENT TEZSPIRE PHASE 2A COPD DATA AT ATS 2024	Apr. 17	AQ
UBS Adjusts Amgen's Price Target to $284 From $314, Maintains Neutral Rating	Apr. 17	MT
Amgen Plans for Phase 3 Trial of Tezepelumab for Lung Disease	Apr. 16	MT
Navigating the Landscape of Precision Medicine in Gastric Cancer: FGFR2b Protein Overexpression as an Emerging Biomarker	Apr. 16	PU
TD Cowen Cuts Price Target on Amgen to $360 From $370, Buy Rating Kept	Apr. 15	MT
Goldman Sachs Adjusts Amgen Price Target to $359 From $361, Maintains Buy Rating	Apr. 15	MT
Neumora's early-stage schizophrenia drug study put on hold	Apr. 15	RE
BMO Lowers Price Target on Amgen to $336 From $343	Apr. 12	MT
Amgen : CEO Bob Bradway's 2023 Letter to Shareholders	Apr. 10	PU
Amgen : Chairman and CEO Letter and Amgen Inc. 2023 Annual Report	Apr. 10	PU
Morgan Stanley Raises 2024, 2025 EPS Estimates for Regeneron Pharmaceuticals, Amgen	Apr. 09	MT
Morgan Stanley Cuts Price Target on Amgen to $271 From $278, Keeps Equalweight Rating	Apr. 09	MT
Boehringer to lay off salespeople as Humira biosimilar sales lag	Apr. 05	RE
Boehringer to lay off salespeople as Humira biosimilar sales lag	Apr. 04	RE
Amgen : How the LATTICE™ Consortium Is Igniting Action and Innovation in Cardiovascular Care	Apr. 04	PU
US takes next step in Medicare drug price negotiations with pharma companies	Apr. 02	RE
Updates On Aflibercept BPCIA Litigation	Mar. 26	AQ
Amgen : Jean-Charles Soria Elected to American Association for Cancer Research Board of Directors	Mar. 19	PU
FDA Approves Sandoz Denosumab Biosimilars	Mar. 18	AQ

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

News Amgen Inc.

Equities

AMGN

US0311621009

Summary

Filters